难治性爱泼斯坦-巴尔病毒（EBV）相关移植后淋巴细胞增生性疾病：通过联合使用维布妥昔单抗和同种异体EBV特异性T淋巴细胞实现治愈
Refractory Epstein-Barr Virus (EBV)-Related Post-transplant Lymphoproliferative Disease: Cure by Combined Brentuximab Vedotin and Allogeneic EBV-Specific T-Lymphocytes.
作者信息
Mika Thomas, Strate Katharina, Ladigan Swetlana, Aigner Clemens, Schlegel Uwe, Tischoff Iris, Tischer-Zimmermann Sabine, Eiz-Vesper Britta, Maecker-Kolhoff Britta, Schroers Roland
机构信息
Department of Medicine, Hematology and Oncology, Ruhr-University Bochum, Bochum, Germany.
Department of Thoracic Surgery, Ruhrlandklinik, University Hospital Essen, Essen, Germany.
出版信息
Front Med (Lausanne). 2019 Dec 18;6:295. doi: 10.3389/fmed.2019.00295. eCollection 2019.
Post-transplant lymphoproliferative disease (PTLD) represents a serious complication following allogeneic hematopoietic stem cell transplantation (alloHSCT). Previously, survival rates of PTLD have improved due to the introduction of rituximab. However, reports on curative management of refractory PTLD are scarce. Today, there is no consensus how to treat rituximab-refractory PTLD, especially in highly aggressive disease. Here, we describe successful management of refractory EBV-associated PTLD, specifically DLBCL, with combined brentuximab vedotin and third-party EBV-specific T-cells in a multidisciplinary treatment approach.
移植后淋巴细胞增生性疾病（PTLD）是异基因造血干细胞移植（alloHSCT）后的一种严重并发症。此前，由于利妥昔单抗的应用，PTLD的生存率有所提高。然而，关于难治性PTLD的治愈性治疗的报道很少。如今，对于如何治疗利妥昔单抗难治性PTLD尚无共识，尤其是在高度侵袭性疾病中。在此，我们描述了采用联合本妥昔单抗和第三方EBV特异性T细胞的多学科治疗方法成功治疗难治性EBV相关PTLD，特别是弥漫性大B细胞淋巴瘤（DLBCL）的案例。
Zotero 插件